{"id":"NCT02366143","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Phase III, Open-Label, Randomized Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03-31","primaryCompletion":"2019-09-13","completion":"2020-12-07","firstPosted":"2015-02-19","resultsPosted":"2020-10-27","lastUpdate":"2021-09-23"},"enrollment":1202,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"interventions":[{"type":"DRUG","name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","otherNames":["MPDL3280A","RO5541267","Tecentriq"]},{"type":"DRUG","name":"Bevacizumab","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Paclitaxel","otherNames":[]}],"arms":[{"label":"Arm A (Atezolizumab+Paclitaxel+Carboplatin)","type":"EXPERIMENTAL"},{"label":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)","type":"EXPERIMENTAL"},{"label":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)","type":"ACTIVE_COMPARATOR"}],"summary":"This randomized, open-label study evaluated the safety and efficacy of atezolizumab (an engineered anti-programmed death-ligand 1 \\[PD-L1\\] antibody) in combination with carboplatin+paclitaxel with or without bevacizumab compared with treatment with carboplatin+paclitaxel+bevacizumab in chemotherapy-naïve participants with Stage IV non-squamous NSCLC. Participants were randomized in a 1:1:1 ratio to Arm A (Atezolizumab+Carboplatin+Paclitaxel), Arm B (Atezolizumab+Carboplatin+Paclitaxel+Bevacizumab), or Arm C (Carboplatin+Paclitaxel+Bevacizumab).","primaryOutcome":{"measure":"Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population","timeFrame":"Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)","effectByArm":[{"arm":"Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin)","deltaMin":11.3,"sd":null},{"arm":"Arm C (Bevacizumab+Paclitaxel+Carboplatin)","deltaMin":6.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":10},"locations":{"siteCount":240,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Bulgaria","Canada","Chile","France","Germany","Italy","Japan","Latvia","Lithuania","Mexico","Netherlands","Peru","Portugal","Russia","Singapore","Slovakia","Spain","Switzerland","Taiwan","Ukraine"]},"refs":{"pmids":["40379995","37545290","36795388","35511917","34626838","34311108","32459597","30922878","29863955"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":142,"n":394},"commonTop":["ALOPECIA","NAUSEA","ANAEMIA","FATIGUE","ARTHRALGIA"]}}